See more : Middle East Healthcare Company (4009.SR) Income Statement Analysis – Financial Results
Complete financial analysis of TELA Bio, Inc. (TELA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TELA Bio, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Great Western Mining Corporation PLC (GWMO.L) Income Statement Analysis – Financial Results
- Petronet LNG Limited (PETRONET.BO) Income Statement Analysis – Financial Results
- Sarveshwar Foods Limited (SARVESHWAR.NS) Income Statement Analysis – Financial Results
- New Gold Inc. (NGD) Income Statement Analysis – Financial Results
- Foran Mining Corporation (FMCXF) Income Statement Analysis – Financial Results
TELA Bio, Inc. (TELA)
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 58.45M | 41.42M | 29.46M | 18.21M | 15.45M | 8.27M | 4.25M |
| Cost of Revenue | 18.34M | 14.37M | 10.65M | 6.98M | 6.17M | 5.33M | 1.71M |
| Gross Profit | 40.11M | 27.04M | 18.81M | 11.23M | 9.27M | 2.94M | 2.53M |
| Gross Profit Ratio | 68.62% | 65.30% | 63.85% | 61.68% | 60.03% | 35.56% | 59.65% |
| Research & Development | 9.62M | 8.94M | 6.74M | 4.26M | 4.15M | 4.34M | 5.79M |
| General & Administrative | 14.89M | 13.86M | 12.46M | 10.14M | 6.22M | 4.90M | 4.96M |
| Selling & Marketing | 59.68M | 43.25M | 29.06M | 22.11M | 18.06M | 13.65M | 8.71M |
| SG&A | 74.57M | 57.11M | 41.52M | 32.25M | 24.28M | 18.55M | 13.67M |
| Other Expenses | 0.00 | -10.00K | -228.00K | 45.00K | 351.00K | 70.00K | 94.00K |
| Operating Expenses | 84.19M | 66.05M | 48.26M | 36.51M | 28.43M | 22.88M | 19.46M |
| Cost & Expenses | 102.53M | 80.43M | 58.91M | 43.49M | 34.61M | 28.22M | 21.17M |
| Interest Income | 0.00 | 4.05M | 3.60M | 3.56M | 3.61M | 0.00 | 0.00 |
| Interest Expense | 5.22M | 4.05M | 3.60M | 3.56M | 3.61M | 1.80M | 4.56M |
| Depreciation & Amortization | 808.00K | 1.19M | 535.00K | 525.00K | 582.00K | 1.25M | 761.00K |
| EBITDA | -40.63M | -39.06M | -29.14M | -24.71M | -18.23M | -18.04M | -16.02M |
| EBITDA Ratio | -69.51% | -94.20% | -100.73% | -138.53% | -121.79% | -225.09% | -378.54% |
| Operating Income | -44.08M | -39.01M | -29.45M | -25.28M | -19.16M | -17.78M | -16.92M |
| Operating Income Ratio | -75.40% | -94.18% | -99.96% | -138.77% | -124.06% | -214.91% | -398.68% |
| Total Other Income/Expenses | -2.59M | -5.29M | -3.83M | -3.52M | -3.26M | -3.31M | -4.41M |
| Income Before Tax | -46.66M | -44.30M | -33.28M | -28.79M | -22.43M | -21.09M | -21.33M |
| Income Before Tax Ratio | -79.83% | -106.95% | -112.94% | -158.10% | -145.18% | -254.92% | -502.57% |
| Income Tax Expense | 0.00 | 41.00K | 2.83M | 3.08M | 3.38M | -1.51M | 4.65M |
| Net Income | -46.66M | -44.34M | -36.11M | -31.88M | -25.80M | -21.09M | -21.33M |
| Net Income Ratio | -79.83% | -107.05% | -122.56% | -175.03% | -167.05% | -254.92% | -502.57% |
| EPS | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| EPS Diluted | -2.04 | -2.73 | -2.49 | -2.46 | -2.26 | -3.25 | -3.29 |
| Weighted Avg Shares Out | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
| Weighted Avg Shares Out (Dil) | 22.87M | 16.27M | 14.47M | 12.93M | 11.41M | 6.49M | 6.49M |
Tecnotree anuncia o lançamento do Sensa, para uma experiência humana inteligente e escalabilidade não linear
ESPOO, Finlândia--(BUSINESS WIRE)--A Tecnotree, uma plataforma digital mundial e líder de serviços para 5G e tecnologias nativas da nuvem, após a aquisição de uma empresa norte-americana de Inteligência artificial (IA) e Aprendizado de máquina (ML) em dezembro de 2022, anunciou...
PopID e Toshiba Global Commerce Solutions realizam parceria para oferecer sistemas biométricos de pontos de venda habilitados e de autoatendimento
RESEARCH TRIANGLE PARK, Carolina do Norte e PASADENA, Califórnia--(BUSINESS WIRE)--A PopID, uma empresa fintech de biometria, e a Toshiba Global Commerce Solutions, a primeira opção de varejo para soluções de comércio unificado, anunciaram uma parceria para a integração do PopPay...
EUROMONITOR REVELA AS 10 PRINCIPAIS TENDÊNCIAS GLOBAIS DE CONSUMO 2023
LONDRES--(BUSINESS WIRE)--A empresa global de pesquisa de mercado, Euromonitor International, divulgou hoje o seu relatório exclusivo “10 Principais Tendências Globais de Consumo 2023”. Esse relatório anual da Euromonitor visa ajudar organizações a ficarem à frente da disrupção, prever motivações de...
TELA Bio, Inc. (TELA) Q3 2022 Earnings Call Transcript
TELA Bio, Inc. (NASDAQ:TELA ) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET Company Participants Greg Chodaczek - Gilmartin Group Tony Koblish - President and CEO Roberto Cuca - COO and CFO Conference Call Participants Frank Takkinen...
TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates
TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
TELA Bio to Announce Third Quarter 2022 Financial Results
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today...
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market
In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer's therapy.
TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption
Shares of TELA Bio have fallen by 40% since public offering in 2019. Differentiation for OviTex versus competitors in terms of clinical outcomes and economics could help them transition from niche player to broad provider.
5 Stocks Insiders Have Built Positions in Over Past 3 Months
According to the Insider Cluster Buys screen, a Premium feature of GuruFocus, five stocks with a high number of insider buy transactions over the past three months include VOXX International Corp. ( VOXX , Financial), Rocket Companies Inc. ( RKT...
TELA Bio to Participate in Upcoming Investor Conferences
MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today...
Source: https://incomestatements.info
Category: Stock Reports